193 related articles for article (PubMed ID: 31819169)
21. HOXB7 promotes tumor progression via bFGF-induced activation of MAPK/ERK pathway and indicated poor prognosis in hepatocellular carcinoma.
Wang WM; Xu Y; Wang YH; Sun HX; Sun YF; He YF; Zhu QF; Hu B; Zhang X; Xia JL; Qiu SJ; Zhou J; Yang XR; Fan J
Oncotarget; 2017 Jul; 8(29):47121-47135. PubMed ID: 28454092
[TBL] [Abstract][Full Text] [Related]
22. Long Noncoding RNA (lncRNA) Small Nucleolar RNA Host Gene 16 (SNHG16) Predicts Poor Prognosis and Sorafenib Resistance in Hepatocellular Carcinoma.
Guo Z; Zhang J; Fan L; Liu J; Yu H; Li X; Sun G
Med Sci Monit; 2019 Mar; 25():2079-2086. PubMed ID: 30893293
[TBL] [Abstract][Full Text] [Related]
23. Elafin promotes tumour metastasis and attenuates the anti-metastatic effects of erlotinib via binding to EGFR in hepatocellular carcinoma.
Wang C; Liao Y; He W; Zhang H; Zuo D; Liu W; Yang Z; Qiu J; Yuan Y; Li K; Zhang Y; Wang Y; Shi Y; Qiu Y; Gao S; Yuan Y; Li B
J Exp Clin Cancer Res; 2021 Mar; 40(1):113. PubMed ID: 33771199
[TBL] [Abstract][Full Text] [Related]
24. The Rho GTPase Rnd1 inhibits epithelial-mesenchymal transition in hepatocellular carcinoma and is a favorable anti-metastasis target.
Qin CD; Ma DN; Zhang SZ; Zhang N; Ren ZG; Zhu XD; Jia QA; Chai ZT; Wang CH; Sun HC; Tang ZY
Cell Death Dis; 2018 May; 9(5):486. PubMed ID: 29706627
[TBL] [Abstract][Full Text] [Related]
25. Activation of ETA Receptor by Endothelin-1 Induces Hepatocellular Carcinoma Cell Migration and Invasion via ERK1/2 and AKT Signaling Pathways.
Cong N; Li Z; Shao W; Li J; Yu S
J Membr Biol; 2016 Apr; 249(1-2):119-28. PubMed ID: 26501871
[TBL] [Abstract][Full Text] [Related]
26. Downregulation of Talin1 promotes hepatocellular carcinoma progression through activation of the ERK1/2 pathway.
Chen P; Lei L; Wang J; Zou X; Zhang D; Deng L; Wu D
Cancer Sci; 2017 Jun; 108(6):1157-1168. PubMed ID: 28375585
[TBL] [Abstract][Full Text] [Related]
27. NOD1 inhibits proliferation and enhances response to chemotherapy via suppressing SRC-MAPK pathway in hepatocellular carcinoma.
Ma X; Qiu Y; Zhu L; Zhao Y; Lin Y; Ma D; Qin Z; Sun C; Shen X; Li T; Han L
J Mol Med (Berl); 2020 Feb; 98(2):221-232. PubMed ID: 31872284
[TBL] [Abstract][Full Text] [Related]
28. HEG1 indicates poor prognosis and promotes hepatocellular carcinoma invasion, metastasis, and EMT by activating Wnt/β-catenin signaling.
Zhao YR; Wang JL; Xu C; Li YM; Sun B; Yang LY
Clin Sci (Lond); 2019 Jul; 133(14):1645-1662. PubMed ID: 31278131
[TBL] [Abstract][Full Text] [Related]
29. EB2 promotes hepatocellular carcinoma proliferation and metastasis via MAPK/ERK pathway by modulating microtubule dynamics.
Zhong FJ; Li YM; Xu C; Sun B; Wang JL; Yang LY
Clin Sci (Lond); 2021 Apr; 135(7):847-864. PubMed ID: 33755094
[TBL] [Abstract][Full Text] [Related]
30. HIF-1α-induced RIT1 promotes liver cancer growth and metastasis and its deficiency increases sensitivity to sorafenib.
Song Z; Liu T; Chen J; Ge C; Zhao F; Zhu M; Chen T; Cui Y; Tian H; Yao M; Li J; Li H
Cancer Lett; 2019 Sep; 460():96-107. PubMed ID: 31247273
[TBL] [Abstract][Full Text] [Related]
31. EGFR-PI3K-PDK1 pathway regulates YAP signaling in hepatocellular carcinoma: the mechanism and its implications in targeted therapy.
Xia H; Dai X; Yu H; Zhou S; Fan Z; Wei G; Tang Q; Gong Q; Bi F
Cell Death Dis; 2018 Feb; 9(3):269. PubMed ID: 29449645
[TBL] [Abstract][Full Text] [Related]
32. The role of EGF-EGFR signalling pathway in hepatocellular carcinoma inflammatory microenvironment.
Huang P; Xu X; Wang L; Zhu B; Wang X; Xia J
J Cell Mol Med; 2014 Feb; 18(2):218-30. PubMed ID: 24268047
[TBL] [Abstract][Full Text] [Related]
33. Ginsenoside Rg3 Decreases NHE1 Expression via Inhibiting EGF-EGFR-ERK1/2-HIF-1
Li X; Tsauo J; Geng C; Zhao H; Lei X; Li X
Am J Chin Med; 2018; 46(8):1915-1931. PubMed ID: 30525897
[TBL] [Abstract][Full Text] [Related]
34. Zinc finger protein 703 induces EMT and sorafenib resistance in hepatocellular carcinoma by transactivating CLDN4 expression.
Wang H; Xu H; Ma F; Zhan M; Yang X; Hua S; Li W; Li Y; Lu L
Cell Death Dis; 2020 Apr; 11(4):225. PubMed ID: 32269215
[TBL] [Abstract][Full Text] [Related]
35. MAT2B mediates invasion and metastasis by regulating EGFR signaling pathway in hepatocellular carcinoma.
Wu L; Chen P; Ying J; Zhang Q; Liu F; Lv B; Che Z; Zhang W; Wu M; Zhang J; Yang D; Liu J
Clin Exp Med; 2019 Nov; 19(4):535-546. PubMed ID: 31493275
[TBL] [Abstract][Full Text] [Related]
36. IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models.
Martinez-Quetglas I; Pinyol R; Dauch D; Torrecilla S; Tovar V; Moeini A; Alsinet C; Portela A; Rodriguez-Carunchio L; Solé M; Lujambio A; Villanueva A; Thung S; Esteller M; Zender L; Llovet JM
Gastroenterology; 2016 Dec; 151(6):1192-1205. PubMed ID: 27614046
[TBL] [Abstract][Full Text] [Related]
37. MicroRNA-294 Promotes Cell Proliferation, Migration and Invasion in SMMC-7721 Hepatoma Carcinoma Cells by Activating the JNK/ERK Signaling Pathway.
Cheng X; Chen M; Liu Z
Am J Med Sci; 2020 Jun; 359(6):365-371. PubMed ID: 32498943
[TBL] [Abstract][Full Text] [Related]
38. TRIM52 up-regulation in hepatocellular carcinoma cells promotes proliferation, migration and invasion through the ubiquitination of PPM1A.
Zhang Y; Tao R; Wu SS; Xu CC; Wang JL; Chen J; Yu YS; Tang ZH; Chen XH; Zang GQ
J Exp Clin Cancer Res; 2018 Jun; 37(1):116. PubMed ID: 29898761
[TBL] [Abstract][Full Text] [Related]
39. C5a receptor enhances hepatocellular carcinoma cell invasiveness via activating ERK1/2-mediated epithelial-mesenchymal transition.
Hu WH; Hu Z; Shen X; Dong LY; Zhou WZ; Yu XX
Exp Mol Pathol; 2016 Feb; 100(1):101-8. PubMed ID: 26475622
[TBL] [Abstract][Full Text] [Related]
40. PI16 attenuates response to sorafenib and represents a predictive biomarker in hepatocellular carcinoma.
Wang P; Jiang Z; Liu X; Yu K; Wang C; Li H; Zhong L
Cancer Med; 2020 Oct; 9(19):6972-6983. PubMed ID: 32779397
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
